⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
CORT News
Corcept Therapeutics Inc.
Corcept Presents New Data at ADA: Improved Outcomes in Patients Receiving a GLP-1 with Difficult-to-Control Type 2 Diabetes and Hypercortisolism Treated with Korlym ®
businesswire.com
CORT
Lifshitz Law PLLC Announces Investigations of Kyndryl Holdings, Inc. (NYSE: KD), Corcept Therapeutics, Inc. (NASDAQ: CORT), NuScale Power Corporation (NYSE: SMR), and Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE)
accessnewswire.com
KD
CORT
SMR
RARE
Form 8-K
sec.gov
CORT
Corcept Presents New Data at ASCO 2026: Lifyorli™ Overall Survival Across All Subgroups of Patients with Platinum-Resistant Ovarian Cancer, Including Those with Recent Taxane Exposure
businesswire.com
CORT
Form 8-K
sec.gov
CORT
Corcept to Resubmit its New Drug Application for Relacorilant as a Treatment for Patients with Cushing’s Syndrome
businesswire.com
CORT
Form 8-K
sec.gov
CORT
Corcept Phase 2 Study of Dazucorilant Demonstrates Two-Year Overall Survival Benefit in Patients with Amyotrophic Lateral Sclerosis
businesswire.com
CORT
Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update
businesswire.com
CORT
Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call
businesswire.com
CORT